Top 15 generic companies are out! The company has 330 andas and 1500 products are on the market every year

In 2016, the top 15 generic pharmaceutical companies were ranked! The top three have total sales of nearly $30 billion Generic drugs are facing global opportunities, especially bio generic drugs At this stage, the volume expansion is only through "buy buy", but for the generic pharmaceutical enterprises whose profit space is limited, cost control is more important How much worse is China's generic drug industry, which is striving for quality improvement and survival of the fittest? According to the latest forecast of e valuate Pharma data, the global generic drug business will grow steadily from US $80 billion in 2016 to US $115 billion in 2022 It is estimated that by 2025, the market size of biological similar drugs will reach 110 billion US dollars Among the top 10 generic pharmaceutical companies in the world, those with sales of more than 9 billion US dollars in 2016 are all existing volume obtained through M & A However, with the rapid growth of the volume, it is impossible to maintain the operation by relying on its own organic growth The opportunities and dilemmas we are facing are basically similar: from the perspective of controlling medical expenses and expanding accessibility, generic drugs are more and more respected; and the common problems we are facing are to be able to copy faster, to win patent challenges and to produce better In the case of TIWA, as the world's largest generics company, it swallowed Elgin's generics business in 2015, with a price of 40.5 billion US dollars, the largest transaction in the field of generics in recent years In 2016, mylan, ranked second in the top 15 pharmaceutical companies in global generic sales, also completed a $7.2 billion acquisition in 2016 It's MEDA in Sweden Through this transaction, mylan obtained a large number of OTC varieties and was able to enter some previously undeveloped emerging markets Now, mylan plans to cut 3500 jobs to save money on acquisitions In third place is Novartis Its core generic business, Sandoz, had sales of $9 billion in 2016 Through sales, we can understand who is the real global leader in generic drugs Pfizer ranked fourth with only $4.6 billion, while Elgin, who has officially left the generic sector, is $4.5 billion Other generic companies on the list include: Sun Pharma of India, Fresenius of Germany, endo of Ireland, Lupin of India, Sanofi of South Africa, Aspen of South Africa, Aurobindo of India, redI of India, sipura of India and Apotex of Canada In addition to price pressure, there are generally launched pricing collusion investigations and more frequent and strict FDA overseas GMP inspections 2008-2022 global generic sales forecast 1 TIWA: big boss worries too What's the big boss of global generic? TIWA announced in 2016 that it plans to launch 1500 products each year, which will achieve an annual growth of 5% "The existing global generic product line allows us to continue to get our first approval opportunity, while the launch of many key generic products will continue to expand the company's product base," Mr Tyva said At present, 330 products of TIWA are pending approval from FDA, 71 of which are expected to be approved in advance, and 95 are the first to apply for listing And the first approval can give TIWA 6 months of market monopoly period In 2016, Tyva obtained 1655 generic drug approvals in Europe alone TIWA is launching airduo respiclick, which is modeled on GSK's heavyweight product, Seretide But Teva itself faces generic competition and is its core product Its blockbuster product, kepasone, in the field of multiple sclerosis, is facing the generic threat of 40 mg dosage forms Tyva has lost several challenge lawsuits against the patent of kepasson in a row The challenger is Sanders Now the world's largest Tyva has other troubles After the $40.5 billion purchase of Elgin's generic business, it has been criticized by investors as "a loss on the purchase! It's not worth the price TIWA, which achieved $9.8 billion in sales in 2016, experienced the experience of replacing the CEO, spending $520 million to settle the bribery charges of the U.S Department of justice, and lowering the company's 2017 performance expectations in just a few months Israeli local media reported that TIWA is considering thousands of layoffs Mylan: Despite the fact that it has been exposed that the price of an important product has increased quietly in the past few years, mylan has become the target of public criticism in the United States But the company's sales remained strong in 2016, reaching $9.43 billion Although the CEO of mylan said publicly that the company's future performance is greatly affected by pricing pressure, the company's growth expectation in 2017 is still as high as 17% Now mylan has more than 7500 products on the market As of 2016, mylan has submitted 243 generic drug listing applications to FDA, and the sales of these listed varieties are nearly $100 billion At the same time, mylan began to increase the distribution of biological similar drugs Currently, its biosimilars for Herceptin have been listed in India, and the application has been submitted to the FDA Mylan has been buying since last year In addition to $7 billion for MEDA, mylan spent $1 billion on a set of topical skin treatments Meanwhile, to save money, mylan plans to cut 3500 jobs 3 Novartis: the price is under pressure Novartis is not only the No.1 in the field of prescription drugs, but also the No.5 in the world in the field of generic drugs because of its sales volume of 9 billion US dollars in 2016 It's worth noting that of the $9 billion in sales, $1 billion is biologically similar The influence of price pressure on Sanders is obvious Sandoz's sales growth in 2016 was 9%, but the overall growth was eroded by 6% due to price issues Although Sandoz will continue to grow in 2017, Novartis executives said that Sandoz's growth rate will be at a low single digit level Some analysts pointed out that although the price pressure continues to grow, generic pharmaceutical companies can only rely on greater M & A, while Novartis has not yet carried out large-scale M & A in the field of generic drugs, except for sanders Pfizer: keep it for cash flow Compared with the brand medicine that makes Pfizer earn a lot of money, the generic medicine business is not so good In 2016, Pfizer's generic business sales were $4.57 billion, which was not the same as the top three Last year, Pfizer's key action in the generic business was to decide not to separate the generic business In 2015, Pfizer spent $15 billion to buy the injection generics company hospita The company has also become a key component of Pfizer's generic business Pfizer said it expects strong and sustainable cash flow Hospita has 220 injection products The generic business is seen by Pfizer as one of the "pillar drivers" of the company's performance growth However, Pfizer will have a fierce battle with TIWA and mylan in the second half of 2017 Because both companies are targeting Pfizer's small blue chip, Viagra In March, Pfizer's antidepressant product, pristiq, expired Sun pharmaceutical: FDA has been in a deep crisis after a heavy blow Although sun pharmaceutical has been repeatedly disclosed as unqualified due to FDA's increased overseas GMP inspection, the company still obtained more than $3 billion in sales in 2016 If we take taro pharmaceutical, which is controlled by sun pharmaceutical, into account, sun pharmaceutical can be ranked fifth In 2016, taro pharmaceutical achieved sales of US $950 million Two years ago, sun pharmaceutical became the largest pharmaceutical company in India through the $4 billion acquisition of rambsi However, rambsi was plagued by scandals due to a series of FDA inspection failures Although the CEO of sun pharmaceutical vowed to completely solve the problem that four factories in lambertino were banned by FDA, sun pharmaceutical's own hospital caught fire Its key generic manufacturing base for the U.S market received a warning letter from the FDA in 2015, which resulted in all new generic applications from the base not being approved Fortunately, sunpharma successfully sent the products of Novartis to the US market Sun pharmaceutical's sales in the United States were significantly boosted by the first approved six-month monopoly period In addition, sun pharmaceutical also began to distribute brand drugs and new drugs to ensure the future development of the company For example, sun pharmaceutical spent 293 million dollars to buy 14 brand drugs with expired patents from Novartis Japan That gives it a bigger advantage in Japan, where the government is expanding its coverage of generics in response to the aging population 6 Freseniuskabi: smash the biological medicine production capacity Freseniuskabi is the generic medicine business of the German Fresenius Medical and health group Its strength lies in the 4% growth in the U.S market This is a company mainly engaged in aseptic injection drugs, and it does biological preparations Although a large number of biopharmaceutical patents are due and the production is difficult, the growth space and pricing space of similar biopharmaceuticals are large, but they also have higher requirements for technology and equipment In 2016, fissenyuskabi announced an investment of US $250 million to transform a production base in the United States into a model workshop for biopharmaceutical production for a period of 10 years In the same year, the company bought a production plant of more than 100000 square meters from bidi The CEO of freseniuskabi said he was considering expanding production capacity in the United States Since July 2016, the company has invested more than US $5.4 billion in aseptic injection generic drugs In April 2017, fesenyuskabi reached another M & a agreement with akorn, a US generic drug company, with a value of US $4.75 billion At the same time, the company also announced plans to acquire Merck's biopharmaceutical business, which is expected to total $729 million Endo: paid 8 billion dollars but bought a failed Endo, an Irish generic drug company that also entered the global ranking through M & A In May 2015, endo announced an $8 billion acquisition of par pharmaceuticals, which resulted in the acquisition of nearly 100 generic products Par Pharmaceutical achieved $1.3 billion in sales in 2014 Everything looks good But the plot turned sharply In March 2016, the company lowered its annual sales forecast from US $4.5 billion to US $4.3 billion The then CEO of the company gave three reasons: new competitors appeared in the market, price pressure exceeded expectations, and the approval process of new products was blocked As a result, Endo's sales in 2016 were only $2.56 billion The company's share price plummeted from $85 to $14 in less than a year 8 lupin: became the fifth largest anda holder by merger and acquisition in May 2016 In Mumbai, India, gavis acquired its first production base in the United States through acquisition of American generic drug company, with an amount of $880 million Meanwhile, it obtained more than 120 brand products and about 60 anda applications submitted to FDA Lupin said that through the acquisition, the company became the fifth largest company applying for FDA anda products in the United States, including 45 first-time applications From April 2016 to March 2017, Lupin launched 13 generic products in the United States One of them is Pfizer's antidepressant product, pristiq, which sold $578 million in 2016 However, mylan and Sandoz are also interested in this product However, products from Lupin's production base in India are also listed on the FDA's import warning list, and the company has conducted two large-scale drug recalls due to substandard raw materials Sanofi: if the growth is not good, sell it! Although Sanofi achieved $2.05 billion in sales in 2016, its European imitations